A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes
Publication
, Conference
Agarwal, R; Locke, FL; Kunnavakkam, R; van Besien, K; Larson, RA; Odenike, O; Godley, L; Liu, H; Le Beau, MM; Gurbuxani, S; Thirman, MJ ...
Published in: BLOOD
November 18, 2011
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 18, 2011
Volume
118
Issue
21
Start / End Page
231 / 232
Location
San Diego, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Agarwal, R., Locke, F. L., Kunnavakkam, R., van Besien, K., Larson, R. A., Odenike, O., … Stock, W. (2011). A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes. In BLOOD (Vol. 118, pp. 231–232). San Diego, CA: AMER SOC HEMATOLOGY.
Agarwal, Rajiv, Frederick L. Locke, Rangesh Kunnavakkam, Koen van Besien, Richard A. Larson, Olatoyosi Odenike, Lucy Godley, et al. “A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes.” In BLOOD, 118:231–32. AMER SOC HEMATOLOGY, 2011.
Agarwal R, Locke FL, Kunnavakkam R, van Besien K, Larson RA, Odenike O, et al. A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes. In: BLOOD. AMER SOC HEMATOLOGY; 2011. p. 231–2.
Agarwal, Rajiv, et al. “A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes.” BLOOD, vol. 118, no. 21, AMER SOC HEMATOLOGY, 2011, pp. 231–32.
Agarwal R, Locke FL, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley L, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins DA, White C, Artz A, Stock W. A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes. BLOOD. AMER SOC HEMATOLOGY; 2011. p. 231–232.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 18, 2011
Volume
118
Issue
21
Start / End Page
231 / 232
Location
San Diego, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology